Cargando…

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer

BACKGROUND: Adjuvant intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) is considered as the first-line agent in patients with high-risk nonmuscle invasive bladder cancer (NMIBC) after surgery. There are no data in India where there is a high prevalence of tubercle bacillus and inherent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshua, Julie Mariam, Vijayan, Meenu, Pooleri, Ginil Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402057/ https://www.ncbi.nlm.nih.gov/pubmed/30858894 http://dx.doi.org/10.1177/1756287219833056

Ejemplares similares

Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection
por: Bijalwan, Priyank, et al.
Publicado: (2017)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
por: Catto, James W. F., et al.
Publicado: (2021)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer
por: Bellat, Vanessa, et al.
Publicado: (2022)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients
por: Kowalski, Mark, et al.
Publicado: (2010)

Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study
por: Jian, Xiaoming, et al.
Publicado: (2019)

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
por: Rao, Manoj V., et al.
Publicado: (2013)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Huang, Haichao, et al.
Publicado: (2014)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection
por: Naya, Yoshio, et al.
Publicado: (2018)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non–muscle-invasive bladder cancer patients
por: Tae, Bum Sik, et al.
Publicado: (2017)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
por: Pak, Sahyun, et al.
Publicado: (2021)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Minimal invasive approaches in lymph node management of carcinoma of penis: A review
por: Kandasamy, Shreedhar Gurunathan, et al.
Publicado: (2022)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6uih1alem701s9k7gdk9udam62